{
  "abstract": "According to the WHO, since 1990 obesity has more than doubled in adults and quadrupled in adolescents. In 2022, one in eight people in the world were obese, including an estimated 160 million aged 5–19 years. More than one in five children are obese when they leave primary school in England, and around two-thirds of obese adolescents will become obese adults. The long-term adverse health risks are well documented (diabetes, metabolic-associated fatty liver disease, cardiovascular disease, certain cancers, etc). In recent analyses combining the costs of healthcare, lost productivity, social care and impacts on quality of life, the total economic burden of obesity in the UK was estimated to be around £126 billion a year.",
  "authors": [
    {
      "affiliations": [
        "Paediatric Gastroenterologist (retired), Leeds Infirmary, Leeds, UK"
      ],
      "name": "John WL Puntis"
    }
  ],
  "title": "Semaglutide for obesity: a pill for every ill?",
  "uid": "abe2c88e-cda9-559b-9ad5-3862536b7ea1"
}